Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 62Gastrointestinal 33Genitourinary 24Head & Neck 18Breast 17Gynecologic 16Lymphoid 9Other solid neoplasm 8Sarcoma 6Plasma cell 4Tumor-Agnostic 3Other hematologic neoplasm 3Endocrine 3CNS 3Dermatologic 2NET 1Myeloid 1

Conditions

Glioblastoma 2Small Cell Lung Carcinoma 1Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × durvalumab × CNS × Clear all
NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Hoosier Cancer Research Network

Phase 2 Terminated
3 enrolled 13 charts
CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT02336165 2022-10-12

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Ludwig Institute for Cancer Research

Phase 2 Completed
159 enrolled 23 charts
CNS

Glioblastoma

NCT02794883 2022-04-18

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Northwestern University

Phase 2 Completed
36 enrolled 13 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡